Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $10.35M |
| Gross Profit (TTM) | $-258.50M |
| EBITDA | $-308.22M |
| Operating Margin | -25950.00% |
| Return on Equity | -36.80% |
| Return on Assets | -22.90% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $4.07 |
| Price-to-Book | 4.44 |
| Price-to-Sales (TTM) | 369.89 |
| EV/Revenue | 296.7 |
| EV/EBITDA | -0.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -48.30% |
| Shares Outstanding | $219.14M |
| Float | $145.48M |
| % Insiders | 1.61% |
| % Institutions | 110.93% |
Volatility is currently expanding
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RLAY and any ticker you trade — then tracks every position and per-strategy win rate.
